SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Derivatives
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (97)4/16/1999 12:42:00 AM
From: sim1  Read Replies (1) of 555
 
Well, this sounds like an exciting event (from Celgene's news release).

Mark your calendars.

THALOMID(TM) (thalidomide) is currently being tested in a phase II clinical study at Cedar's Sinai, Los Angeles for its use in Crohn's Disease. Preliminary findings from this trial will be presented at Digestive Disease Week, May 16-19, 1999 in Orlando, FL.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News